WuXi AppTec Co Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
3 / 240
Position in country
163 / 7387
Return on Assets, %
13.9
-2.7
Net income margin, %
20.2
-6.7
EBITDA margin, %
34.6
5.6
Debt to Equity, %
10.4
15.1
Intangible assets and goodwill, %
5
4.7
Revenue CAGR 3Y, %
34.6
12.8
Total Equity change 1Y, %
14.9
-2.4
Revenue Y, % chg
-2.7
0
P/E
13.2
32.1
P/BV
2.3
2
P/S
3.1
4.1
EV/S
2.8
3.6
EV/EBITDA
10
7.8
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
153.8
48.9
Forward P/E
11.6
25.5
Dividend Yield, %
2.7
0.8
Forward Dividend Yield, %
3.2
0.2
Expected dividend per share
0.1
0
Payout Ratio, %
30
10.1
Dividend Ex Date
2023-06-05
Competitors
Ranks
-
WuXi AppTec Co Ltd
00%
-
Pharmaron Beijing Co Ltd
00%
-
WuXi XDC Cayman Inc
00%
-
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd
00%
-
Joinn Laboratories China Co Ltd
00%
-
WuXi Biologics (Cayman) Inc
00%
-
Genscript Biotech Corp
00%
-
Shanghai Runda Medical Technology Co Ltd
00%
-
Hangzhou Tigermed Consulting Co Ltd
00%
-
MGI Tech Co Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
China
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Life Sciences Tools & Services
Sub-sector
Health Care
Capitalization (millions of $)
16823.1
Ticker
WUXAY.PK
ISIN
US98260P1030
IPO date
2018-05-08
Availability on Russian exchanges
Yes
Reporting for
2024-03-18
Date fact. publication of reports
2023-12-31
Company Description
WuXi AppTec Co., Ltd. is a China-based investment holding company principally engaged in the provision of new drug research and development (R&D), production and supporting services, as well as related technology platform services. The Company is mainly engaged in the discovery, development and production of small molecule drugs, cell therapies and gene therapies, as well as providing testing services for medical devices. The Company mainly conducts its businesses through four segments, including China-based Laboratory Services segment, Contract Manufacturing organization/contract development and manufacturing organization services (CMO/CDMO services) segment, US-based Laboratory Services segment and Clinical Research segment.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: